Liver Steatosis is Prevalent in Lean People With HIV and Associated With Exposure to Antiretroviral Treatment—A Cross-sectional Study

作者：Louise E. van Eekeren, Nadira Vadaq, Wilhelm A. J. W. Vos, Marc J. T. Blaauw, Albert L. Groenendijk, Jan van Lunzen, Janneke E. Stalenhoef, Marvin A. H. Berrevoets, Annelies Verbon, Gert Weijers, Mihai Gheorghe Netea, Andre J. A. M. van der Ven, Quirijn de Mast, Leo A. B. Joosten, Eric T.T.L. Tjwa · 发表于：Open Forum Infectious Diseases · 年份：2024 · DOI：10.1093/ofid/ofae266 · 被引用次数：11 · 研究领域：HIV-related health complications and treatments、Liver Disease Diagnosis and Treatment、Diabetes, Cardiovascular Risks, and Lipoproteins

Abstract Background Steatotic liver disease is suggested to have a higher prevalence and severity in people with HIV (PHIV), including in those with a normal body mass index (BMI). In this study, we used data from the 2000HIV cohort to (1) assess the prevalence of liver steatosis and fibrosis in lean versus overweight/obese PHIV and (2) assess associations in these subgroups between steatosis and fibrosis with traditional risk factors and HIV-specific characteristics. Methods The 2000HIV study cohort comprises 1895 virally suppressed PHIV that were included between 2019 and 2021 in 4 HIV treatment centers in the Netherlands. The majority (58.5%) underwent vibration-controlled transient elastography for the assessment of liver steatosis and fibrosis. The prevalence of steatosis (controlled attenuation parameter ≥263 dB/m) and fibrosis (liver stiffness measurement ≥7.0 kPa) was estimated. Multiple factors including HIV characteristics and antiretroviral drugs were tested in a logistic regression model for association with steatosis and fibrosis. Analyses were performed separately for lean (Asian descent: BMI < 23 kg/m2, other descent: BMI < 25 kg/m2) and overweight/obese (other BMI) participants. Results Of 1050 PHIV including 505 lean and 545 overweight/obese PHIV, liver steatosis was observed in 37.7% of the overall study population, 19.7% of lean, and 54% of overweight/obese PHIV, whereas fibrosis was observed in 9.0% of the overall study population, 5.9% of lean, and 12.0% ...